Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...
Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The ...
REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...
We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may ...
Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
In a report released on March 14, Luca Issi from RBC Capital maintained a Buy rating on RegenXBio (RGNX – Research Report), with a price target ...
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...
(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...
Stocktwits on MSN1d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving UpShares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback